Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SI | P14410 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TPO | P07202 | 1/20 | 0.51 |
| ▸ | EPX | P11678 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899683 | 0.89 | NPC1 (0.48) | RAB9ASMN1; SMN2NPC1CXCR2CX3CR1 | |
| SCHEMBL6635771 | 0.84 | CYP3A4 (0.56) | GAARAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL6639107 | 0.84 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1TP53KDM4E | |
| SCHEMBL13067222 | 0.83 | MGAM (0.51) | MGAMGAASIMGAM2MPO | |
| SCHEMBL1520900 | 0.83 | MPO (0.54) | MGAMGAASIMGAM2MPO | |
| SCHEMBL6637576 | 0.82 | NPC1 (0.48) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL13402259 | 0.80 | ALDH1A1 (0.56) | MPORAB9ASMN1; SMN2NPC1CTSB | |
| SCHEMBL1520770 | 0.79 | RAB9A (0.78) | GAARAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL490245 | 0.78 | CXCR2 (0.50) | CXCR2 | |
| SCHEMBL3853163 | 0.78 | RAB9A (0.57) | MPORAB9ASMN1; SMN2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958344-B2 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-10-20 | — | — | US | disclosed |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1265899-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001058902-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CCR5, CXCR1, CXCR4 | MGAM 4397/4885GAA 3505/4885SI 3430/4885 |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR2 | MGAM 4413/4885GAA 3558/4885SI 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.